• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种实用算法的开发与应用,以指导确定碳青霉烯酶检测以鉴定产碳青霉烯酶的情况

Development and Application of a Pragmatic Algorithm to Guide Definitive Carbapenemase Testing to Identify Carbapenemase-Producing .

作者信息

Gill Christian M, Asempa Tomefa E, Nicolau David P

机构信息

Center for Anti-Infective Research and Development, Hartford Hospital, Hartford, CT 06102, USA.

Division of Infectious Diseases, Hartford Hospital, Hartford, CT 06102, USA.

出版信息

Antibiotics (Basel). 2020 Oct 27;9(11):738. doi: 10.3390/antibiotics9110738.

DOI:10.3390/antibiotics9110738
PMID:33120865
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7693613/
Abstract

A minimum inhibitory concentration (MIC) derived algorithm, predictive of carbapenemase production, was developed using a challenge set ( = 92) of (PA), including carbapenemase-producing (CP), cephalosporinase and/or efflux/porin mutation, and wild-type isolates. Broth microdilution MICs to clinically relevant anti-pseudomonal agents were utilized. The algorithm was applied to 1209 clinical PA isolates from a US surveillance program. Confirmatory genotypic (Xpert Carba-R assay) and phenotypic (mCIM/eCIM) testing for carbapenemases was conducted on algorithm-derived isolates. With the algorithm, carbapenem resistance alone resulted in poor specificity to identify CP-PA (54%) within the challenge set of isolates. Inclusion of cefepime, ceftazidime, and piperacillin/tazobactam non-susceptibility resulted in a specificity of 66%. Ceftolozane/tazobactam resistance further improved specificity (89%). Of the 1209 isolates, 116 met criteria (carbapenem-resistant and non-susceptibility to cefepime, ceftazidime, and piperacillin/tazobactam) for confirmatory testing. Carba-R and mCIM/eCIM identified five (all -positive) and seven carbapenemase-producing isolates, respectively. This MIC algorithm combined with genotypic/phenotypic carbapenemase testing is a pragmatic and streamlined approach to identify CP-PA.

摘要

利用一组包含92株铜绿假单胞菌(PA)的挑战集开发了一种预测碳青霉烯酶产生的最低抑菌浓度(MIC)衍生算法,其中包括产碳青霉烯酶(CP)、头孢菌素酶和/或外排/孔蛋白突变菌株以及野生型菌株。采用肉汤微量稀释法测定了对临床相关抗假单胞菌药物的MIC。该算法应用于美国一项监测项目中的1209株临床PA分离株。对算法得出的分离株进行了碳青霉烯酶的确认性基因检测(Xpert Carba - R检测)和表型检测(mCIM/eCIM)。在分离株挑战集中,仅碳青霉烯耐药对鉴定产碳青霉烯酶的PA(CP - PA)特异性较差(54%)。纳入头孢吡肟、头孢他啶和哌拉西林/他唑巴坦不敏感结果后,特异性为66%。头孢洛扎/他唑巴坦耐药进一步提高了特异性(89%)。在1209株分离株中,有116株符合确认性检测标准(碳青霉烯耐药且对头孢吡肟、头孢他啶和哌拉西林/他唑巴坦不敏感)。Carba - R检测和mCIM/eCIM分别鉴定出5株(均为阳性)和7株产碳青霉烯酶的分离株。这种MIC算法结合基因/表型碳青霉烯酶检测是一种实用且简化的鉴定CP - PA的方法。

相似文献

1
Development and Application of a Pragmatic Algorithm to Guide Definitive Carbapenemase Testing to Identify Carbapenemase-Producing .一种实用算法的开发与应用,以指导确定碳青霉烯酶检测以鉴定产碳青霉烯酶的情况
Antibiotics (Basel). 2020 Oct 27;9(11):738. doi: 10.3390/antibiotics9110738.
2
Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Using the ERACE-PA Global Surveillance Program.使用ERACE-PA全球监测计划对一种用于指导耐碳青霉烯类细菌碳青霉烯酶检测的表型算法进行多中心前瞻性验证。
Open Forum Infect Dis. 2021 Dec 13;9(2):ofab617. doi: 10.1093/ofid/ofab617. eCollection 2022 Feb.
3
Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized patients.耐碳青霉烯铜绿假单胞菌:对 ICU 与非 ICU 分离株的频率、住院患者的表型和基因型特征的跨国人群评估。
Antimicrob Resist Infect Control. 2022 Nov 30;11(1):146. doi: 10.1186/s13756-022-01187-8.
4
Evaluation of a Phenotypic Algorithm to Direct Carbapenemase Testing in : Validation in a Multicenter German Cohort.评价表型算法在 : 多中心德国队列中的碳青霉烯酶检测中的应用。验证。
Microb Drug Resist. 2021 Sep;27(9):1243-1248. doi: 10.1089/mdr.2020.0476. Epub 2021 Jan 8.
5
Activity of Ceftolozane-Tazobactam against Carbapenem-Resistant, Non-Carbapenemase-Producing Pseudomonas aeruginosa and Associated Resistance Mechanisms.头孢他洛滨-他唑巴坦对产碳青霉烯酶非产碳青霉烯酶耐药铜绿假单胞菌的活性及相关耐药机制。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01970-17. Print 2018 Jan.
6
Multicenter Evaluation of the Modified Carbapenem Inactivation Method and the Carba NP for Detection of Carbapenemase-Producing Pseudomonas aeruginosa and Acinetobacter baumannii.多中心评价改良碳青霉烯酶灭活法和 Carba NP 检测产碳青霉烯酶铜绿假单胞菌和鲍曼不动杆菌。
J Clin Microbiol. 2017 Dec 26;56(1). doi: 10.1128/JCM.01369-17. Print 2018 Jan.
7
Evaluation of phenotypic detection of carbapenemase-producing Pseudomonas spp. from clinical isolates.评价临床分离的产碳青霉烯酶铜绿假单胞菌的表型检测。
Braz J Microbiol. 2023 Mar;54(1):135-141. doi: 10.1007/s42770-022-00857-4. Epub 2022 Nov 3.
8
Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers.意大利全国侵袭性感染铜绿假单胞菌调查:头孢洛扎/他唑巴坦和对照药物的活性,以及产碳青霉烯酶者的分子流行病学。
J Antimicrob Chemother. 2018 Mar 1;73(3):664-671. doi: 10.1093/jac/dkx453.
9
Determination of the presence of carbapenemase enzymes in carbapenem-resistant Pseudomonas aeruginosa isolates by susceptibility test based algorithm.基于药敏试验算法检测耐碳青霉烯铜绿假单胞菌分离株中碳青霉烯酶的存在。
Diagn Microbiol Infect Dis. 2024 Dec;110(4):116495. doi: 10.1016/j.diagmicrobio.2024.116495. Epub 2024 Aug 14.
10
Modified Carbapenem Inactivation Method and Ethylenediaminetetraacetic Acid (EDTA)-Carbapenem Inactivation Method for Detection of Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa.用于检测产碳青霉烯酶肠杆菌科细菌和铜绿假单胞菌的改良碳青霉烯灭活法及乙二胺四乙酸(EDTA)-碳青霉烯灭活法
Cureus. 2024 Jun 27;16(6):e63340. doi: 10.7759/cureus.63340. eCollection 2024 Jun.

引用本文的文献

1
Investigating the validity of mCIM and sCIM phenotypic methods in screening Pseudomonas aeruginosa isolates producing IMP, VIM, and NDM metallo-beta-lactamases isolated from burn wounds.研究微量肉汤稀释法(mCIM)和纸片扩散法(sCIM)表型方法在筛选从烧伤创面分离出的产IMP、VIM和NDM金属β-内酰胺酶的铜绿假单胞菌菌株中的有效性。
J Antibiot (Tokyo). 2025 Mar;78(4):256-264. doi: 10.1038/s41429-025-00806-x. Epub 2025 Jan 21.
2
Antibiotic susceptibility of in Saudi Arabia: a national antimicrobial resistance surveillance study.沙特阿拉伯耐抗生素的 :一项全国性的抗菌药物耐药性监测研究。
Front Public Health. 2024 Sep 30;12:1436648. doi: 10.3389/fpubh.2024.1436648. eCollection 2024.
3

本文引用的文献

1
Implementing carbapenem-resistance testing algorithms for Enterobacteriales and Pseudomonas aeruginosa: diagnostic and antimicrobial stewardship with timely infection prevention.实施针对肠杆菌科细菌和铜绿假单胞菌的碳青霉烯类耐药性检测算法:通过及时预防感染进行诊断和抗菌药物管理。
Diagn Microbiol Infect Dis. 2020 Aug;97(4):115069. doi: 10.1016/j.diagmicrobio.2020.115069. Epub 2020 Apr 30.
2
Dissemination of carbapenem-resistant Pseudomonas aeruginosa isolates and their susceptibilities to ceftolozane-tazobactam in Germany.德国碳青霉烯类耐药铜绿假单胞菌的传播及其对头孢他啶-他唑巴坦的药敏情况。
Int J Antimicrob Agents. 2020 Jun;55(6):105959. doi: 10.1016/j.ijantimicag.2020.105959. Epub 2020 Apr 20.
3
Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant .
定向碳青霉烯酶检测不再仅仅针对肠杆菌科:扩大碳青霉烯酶检测至碳青霉烯类耐药的成本、劳动力和工作流程评估。
Emerg Microbes Infect. 2023 Dec;12(1):2179344. doi: 10.1080/22221751.2023.2179344.
4
Carbapenemase-producing -an emerging challenge.产碳青霉烯酶 - 新出现的挑战。
Emerg Microbes Infect. 2022 Dec;11(1):811-814. doi: 10.1080/22221751.2022.2048972.
5
Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant Using the ERACE-PA Global Surveillance Program.使用ERACE-PA全球监测计划对一种用于指导耐碳青霉烯类细菌碳青霉烯酶检测的表型算法进行多中心前瞻性验证。
Open Forum Infect Dis. 2021 Dec 13;9(2):ofab617. doi: 10.1093/ofid/ofab617. eCollection 2022 Feb.
6
Success and Challenges Associated with Large-Scale Collaborative Surveillance for Carbapenemase Genes in Gram-Negative Bacteria.大规模协作监测革兰氏阴性菌碳青霉烯酶基因的成功与挑战。
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0229921. doi: 10.1128/aac.02299-21. Epub 2021 Dec 20.
7
The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa.ERACE-PA 全球监测计划:头孢他啶/他唑巴坦和头孢他啶/阿维巴坦对全球碳青霉烯类耐药铜绿假单胞菌的体外活性。
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2533-2541. doi: 10.1007/s10096-021-04308-0. Epub 2021 Jul 22.
8
Antimicrobial Susceptibility Profiles To Predict the Presence of Carbapenemase Genes among Carbapenem-Resistant Pseudomonas aeruginosa Isolates.抗微生物药敏谱分析预测耐碳青霉烯铜绿假单胞菌分离株中碳青霉烯酶基因的存在。
J Clin Microbiol. 2021 May 19;59(6). doi: 10.1128/JCM.02874-20.
Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017-2018).
比较头孢他啶-阿维巴坦和头孢洛扎-他唑巴坦对 2017-2018 年美国医疗中心住院肺炎患者分离的革兰氏阴性菌的体外活性。
Diagn Microbiol Infect Dis. 2020 Mar;96(3):114833. doi: 10.1016/j.diagmicrobio.2019.05.005. Epub 2019 May 10.
4
Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase-Producing Gram-Negative Bacteria?氨曲南联合疗法:应对产金属β-内酰胺酶革兰氏阴性菌的解决方案?
Clin Infect Dis. 2020 Aug 14;71(4):1099-1101. doi: 10.1093/cid/ciz1159.
5
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.革兰氏阴性菌碳青霉烯类耐药的流行病学和诊断学。
Clin Infect Dis. 2019 Nov 13;69(Suppl 7):S521-S528. doi: 10.1093/cid/ciz824.
6
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.头孢他洛赞/他唑巴坦与多粘菌素或基于氨基糖苷类的方案治疗耐多药铜绿假单胞菌的比较
Clin Infect Dis. 2020 Jul 11;71(2):304-310. doi: 10.1093/cid/ciz816.
7
Characterization of carbapenem-resistant and XDR Pseudomonas aeruginosa in Canada: results of the CANWARD 2007-16 study.加拿大耐碳青霉烯类和广泛耐药铜绿假单胞菌的特征:CANWARD 2007-16 研究结果。
J Antimicrob Chemother. 2019 Aug 1;74(Suppl 4):iv32-iv38. doi: 10.1093/jac/dkz285.
8
Antibiotic resistance in Pseudomonas aeruginosa - Mechanisms, epidemiology and evolution.铜绿假单胞菌的抗生素耐药性-机制、流行病学和进化。
Drug Resist Updat. 2019 May;44:100640. doi: 10.1016/j.drup.2019.07.002. Epub 2019 Jul 19.
9
potency of antipseudomonal β-lactams against blood and respiratory isolates of collected from US hospitals.抗假单胞菌β-内酰胺类药物对从美国医院收集的血液和呼吸道分离菌株的抗菌效力。
J Thorac Dis. 2019 May;11(5):1896-1902. doi: 10.21037/jtd.2019.05.13.
10
Extensively Drug-Resistant ST309 Harboring Tandem Guiana Extended Spectrum β-Lactamase Enzymes: A Newly Emerging Threat in the United States.携带串联圭亚那超广谱β-内酰胺酶的广泛耐药性ST309:美国新出现的威胁
Open Forum Infect Dis. 2019 Jun 6;6(7):ofz273. doi: 10.1093/ofid/ofz273. eCollection 2019 Jul.